Management of Wolff-Parkinson-White syndrome in a patient with peripartum cardiomyopathy

Snigdha Bendaram, Sherif Elkattawy, Muhammad Atif Masood Noori, Hardik Fichadiya, Sarah Ayad, Parminder Kaur, Raja Pullatt and Fayez Shammo

ABSTRACT
Wolf-Parkinson-White (WPW) syndrome is a congenital heart condition in which the atrioventricular (AV) node is bypassed by an accessory pathway that connects the atria and ventricle directly along with symptoms of syncope or palpitations. WPW syndrome in patients with a history of peripartum cardiomyopathy (pregnancy-related cardiomyopathy) is associated with a high risk of morbidity and mortality secondary to failure of the pump and the conduction system of the heart. Management of these cases deals with arrhythmia and systolic heart failure, which becomes more challenging in pregnant patients as it requires treatment methods that minimize risks to the fetus. We report a case of a young female patient with WPW syndrome and peripartum cardiomyopathy presenting with symptomatic arrhythmias (tachycardia).

1. Introduction
Wolf-Parkinson-White (WPW) syndrome is a congenital heart disease in which an accessory pathway directly connects the atria and ventricle, bypassing the atrioventricular (AV) node along with symptoms of syncope or palpitations. The characteristic WPW pattern EKG includes a short PR interval (0.12 seconds) and a delta wave with a wide (0.12 seconds) QRS complex. The delta wave results from rapid ventricular activation via the accessory pathway (preexcitation). In the general population, the prevalence of WPW pattern EKG is around 0.13 to 0.25%. In comparison, prevalence of WPW syndrome is as low as 2% of patients with WPW patterns on surface EKG.

Diagnostic criteria involve pre-existing WPW patterns on EKG and arrhythmia involving the accessory pathway. Asymptomatic adults with WPW patterns are generally not treated. In contrast, those with symptomatic arrhythmias should be treated. We report a case of a young female patient with WPW syndrome and peripartum cardiomyopathy presenting with symptomatic arrhythmias (tachycardia).

2. Case presentation
29-year-old African American female with a past medical history of opiate abuse and currently two months into her post-partum period presented to ED complaining of constant, sharp left-sided chest pain for the past four days which was mildly relieved with ibuprofen. She described it to be exacerbated by deep breaths and associated with cough and blood-tinged sputum. She endorsed palpitations lasting all day long and two episodes of non-bloody, non-bilious emesis. She also reported bilateral lower extremity edema with associated orthopnea and PND. Of note, she is bed-bound most of the time, secondary to her lower extremity swelling.

This was her fourth pregnancy and she reported having similar symptoms in her prior post-partum periods as well but was never formally evaluated.

In ED, the patient was found to have a BP of 76/50. EKG (EKG a) showed Narrow complex tachycardia with a nonspecific intraventricular block and a heart rate of 190 beats per minutely mechanism being orthodromic AVRT given presence of delta wave in prior resting EKG. Also, a QTc of 533 milliseconds was noted. Serum magnesium was 1.6 mg/dl, which was repleted. She was treated with two doses of 100 mg intravenous procainamide, which reverted the cardiac rhythm to sinus rhythm and raised the patients blood pressure to 110/70 mmHg. A white blood cell count of 12,400/mm3 (Normal range 4,000–10,000) was noted. Brain natriuretic peptide levels were 916 pg/ml (Normal <100). Chest X-ray showed findings suggestive of a small left pleural effusion; CT angiography was negative for Pulmonary embolism but did show findings concerning left lower lobe bronchopneumonia with trace pericardial and bilateral pleural effusions. The patient was given ceftriaxone and doxycycline, was continued on procainamide infusion and admitted to the Intensive care unit for further management.

Cardiology was consulted, a transthoracic echocardiogram showed a left ventricular ejection fraction of less than 20% with moderate left ventricular
hypertrophy and a moderate to severe tricuspid regurgitation. The following day, an electrocardiogram showed conversion to sinus rhythm and WPW pattern with a heart rate of 100bpm to 120bpm (EKG b). Procainamide was eventually discontinued, and she was started on intravenous furosemide infusion. Serum magnesium of greater than 2 mg/dl and potassium levels of greater than four mmol/l were maintained. The patient remained afebrile with improving leukocytosis; MRSA screen was negative, and blood cultures did not show any growth. She was continued on Ceftriaxone 2 g IV daily and doxycycline 100 mg PO BID given her QTc prolongation.

The patient was then transferred to a tertiary facility for further management of the accessory pathway and Congestive heart failure. There docratamine and milrinone infusions were started for ionotropic support and the patient is now being evaluated for left ventricular assist device implantation.

### 3. Discussion

Peripartum Cardiomyopathy (PPCM), also called pregnancy-associated cardiomyopathy, is an uncommon cause of heart failure during late pregnancy or early postpartum period. It is associated with significant morbidity and mortality related to heart failure and arrhythmias, which usually result from stretching of atrial and ventricular chambers [1,2]. It is estimated to account for less than 1% of pregnancy-associated cardiovascular complications, but the incidence has been increasing. In a large inpatient-based study on 9841 patients hospitalized for PPCM, 18.7% of the patients had an arrhythmia, of which 4.2% had ventricular arrhythmia, and 2.2% suffered cardiac arrest [3,4]. WPW syndrome is a pre-excitation/accessory pathway-induced arrhythmia associated with pregnancy and can be seen in combination with PPCM, which involves simultaneous management of systolic dysfunction and can get challenging at times.

Management of arrhythmias during pregnancy is more or less similar to that of a non-pregnant state. However, care should be taken to avoid any detrimental effects on fetal well-being due to therapy or the underlying condition. Several AV nodal blocking agents are considered safe for supraventricular tachycardia during pregnancy; however, in patients with WPW syndrome, AV nodal blocking agents are contraindicated or are cautiously used due to the potential for life-threatening ventricular fibrillation [5]. Class IA antiarrhythmics like procainamide, quinidine, and Class IC antiarrhythmics like propafenone, flecaïnide are considered safe when there is no associated ischemic or structural heart disease. For these reasons, managing patients with WPW syndrome and simultaneous PPCM is a challenge and requires multidisciplinary team management as PPCM therapy involves using beta-blockers to manage the underlying heart failure.

In comparison, Class IC drugs are associated with a better benefit/risk ratio, whereas Class IA drugs have been noticed to be less potent than Class IC drugs and are associated with intolerable side effects [6,7]. Procainamide produces a lengthening of the refractory period of the accessory pathway in AVRT or of the fast pathway in AVNRT to terminate the re-
entry tachycardia [8]. Beta blocking agents are occasionally used to suppress orthodromic AVRT in those with WPW syndrome with a low risk of ventricular tachyarrhythmias due to pre-excitation. Of note, AVRT occurs in two types: orthodromic and antidromic. Orthodromic AVRT re-entry impulse circulates in an antegrade direction through the AV node; in antidromic AVRT, the impulse travels in a retrograde direction through the AV node.

Amiodarone is effective but has significant side effects; thus, it can be employed in patients where other therapies failed or are not feasible. As per 2014 AHA guidelines, for patients with pre-excitation and rapid ventricular rate, management involves intravenous procainamide in hemodynamically stable patients and synchronized cardioversion in unstable ones. In a small, non-randomized trial containing a subset of patients with AVRT, ten patients treated with a combination of propafenone and beta-blocker therapy had no recurrence at >9 months after discharge [9]. Cardioversion can be performed during any week of pregnancy; although there is a theoretical risk of triggering an arrhythmia in the fetus, the risk is supposed to be small due to the small amount of energy directly reaching the fetus itself [10,11]. However, there have been cases reported of fetal arrhythmias requiring emergent C-section after cardioversion, and hence monitoring fetal heart rhythm is recommended [12].

As per 2015 ACC/AHA/HRC guidelines, vagal maneuvers and IV adenosine are Class I A recommendations for orthodromic AVRT. In a hemodynamically stable patient where vagal maneuvers or adenosine is ineffective or not feasible, radiofrequency ablation can be performed as a class I recommendation irrespective of the patient’s EKG demonstrating pre-excitation. If the patient is unstable, synchronized cardioversion is recommended (Class I).

If the patient has pre-excitation and is unwilling to undergo ablation, medications including flecainide or propafenone (in the absence of structural heart disease (SHD)) can be used as Class IIa recommendations. Amiodarone, beta-blockers, diltiazem, dofetilide, sotalol, or verapamil can be used as Class IIb recommendation. There is a class I recommendation for beta-blockers, diltiazem, or verapamil if there is no pre-excitation. If any of the aforementioned medications in the presence or absence of pre-excitation are ineffective, it is a class I indication for ablation.

After an acute event, radiofrequency ablation of the accessory pathway is recommended to prevent recurrent episodes of arrhythmia in patients with WPW syndrome. This procedure is generally avoided during pregnancy due to the risk of exposure of the fetus to ionizing radiation. However, as the amount of radiation is small and only involves the area of the thorax of the mother for the procedure, patients with drug-resistant and severe arrhythmias during pregnancy can be considered for this procedure provided adequate precautionary measures to minimize fetal radiation exposure are undertaken [131415].

4. Conclusion

Although peripartum cardiomyopathy is rare, it is associated with significant morbidity and mortality

![EKG b](image-url)
from both systolic heart failure and arrhythmias’ especially in cases of underlying WPW syndrome. Treatment involves using class Ia and III antiarrhythmic agents. Beta-blockers can also be used to manage heart failure in patients with orthodromic AVRT and low risk of ventricular arrhythmia.

Unstable patients need synchronized cardioversion, which carries a risk of fetal arrhythmia, and fetal cardiac monitoring is recommended during the procedure.

Disclosure statement
No potential conflict of interest was reported by the author(s).

ORCID
Snigdha Bendaram http://orcid.org/0000-0002-3616-7027
Parminder Kaur http://orcid.org/0000-0002-7015-3489

References
[1] Burden of arrhythmias in peripartum cardiomyopathy: Analysis of 9841 hospitalizations- SagarMallikethi-Reddy, Emmanuel Akinbode, NaveenTrehan, ShikhaSharma, AlexandrosBriasoulis, KavyashriJagadeesh, MelvinRubenfire, Cindy LGrines, LuisAfonso
[2] Detection and management of arrhythmias in peripartum cardiomyopathy Julian
[3] Hoevelmann1,2#, Lina Hähnle1#, Julia Hähnle1, Karen Sliwa1,3, Charle Viljoen1,3
[4] Honigberg MC, Givertz MM. Arrhythmias in peripartum cardiomyopathy. Card Electrophysi Clin. 2015;7:309.
[5] Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Murray, K. T., Sacco, R. L., Stevenson, W. G., Tchou, P. J., Tracy, C. M., Yancy, C. W., & ACC/AHA Task Force Members (2014). 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation, 130(23), 2071–2104. https://doi.org/10.1161/CIR. 0000000000000040
[6] Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias: executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-heart rhythm society. J Am Coll Cardiol. 2003;42:1493–1531. [PubMed] [Google Scholar].
[7] Cox JL, Gardner MJ. Treatment of cardiac arrhythmias during pregnancy. Prog Cardiovasc Dis. 1993;36:137.
[8] Damilakis J, Theocharopoulos N, Perisinakis K, et al. Conceptus radiation dose and risk from cardiac catheter ablation procedures. Circulation. 2001;104:893.
[9] Page RL. Treatment of arrhythmias during pregnancy. Am Heart J. 1995;130:871.
[10] Janousek J, Paul T, Reimer A, et al. Usefulness of propafenone for supraventricular arrhythmias in infants and children. Am J Cardiol. 1993;72:294–300.
[11] Tan HL, Lie KI. Treatment of tachyarrhythmias during pregnancy and lactation. Eur Heart J. 2001;22:458.
[12] DeSilva RA, Graboys TB, Podrid PJ, et al. Cardioversion and defibrillation. Am Heart J. 1980;100:881.
[13] Barnes EJ, Eben F, Patterson D. Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG. 2002;109:1406.
[14] Goy JJ 1, Fromer M. Antiarrhythmic treatment of atrioventricular tachycardias. J Cardiovasc Pharmacol. 1991;17(Suppl 6):S36–40.
[15] Page, Richard L, Joglar J, et al. 2015. ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2015.